Xilis Inc, based in Durham, NC, is revolutionizing precision oncology and drug development with their MicroOrganoSphereTM (MOS) technology. Developed by world-class scientists, their platform enables rapid diagnostics for personalized therapy prioritization, high-throughput drug discovery, and patient-centric solutions for cancer drug development.
With their Precision Oncology Platform, Xilis empowers clinicians to make informed treatment decisions by predicting patient response and guiding optimal therapeutic options. Their breakthrough technology provides cost-effective screening, personalized assays, and companion diagnostics to guide patients to newly developed treatments.
Generated from the website